Preliminary Q1 2026 Results: Revenue and Operating Profit Decline, Net Income Turns Positive


  • Consolidated preliminary Q1 2026 results: Revenue 235.5bn KRW (YoY -11.1%), Operating profit 2.9bn (-41.1%), Net income 2.2bn (swing to profit)
  • QoQ changes: Revenue -6.0%, Operating profit -25.1%, Net income -33.7% (previous quarter net income 33.3bn)
  • Controlling interests net income 14.5bn (swing from -66.2bn in prior year same period)
  • Figures are preliminary and unaudited, subject to change

KOSDAQ Filing Information


  • Consolidated Financial Statements Basis Operating (Provisional) Results (Fair Disclosure)
  • Company: Green Cross Medical Science (142280)
  • Submission: Green Cross Medical Science Corporation
  • Under KRX KOSDAQ Market Division

  • Shares: 21,741,926
  • Price: 3,870 KRW
  • Market Cap: 84.1 B KRW